We read the article entitled "Lower in-hospital ventricular tachyarrhythmia in patients with acute myocardial infarction receiving prior statin therapy" by Park et al 1 with interest. They reported that previous statin therapy was associated with a reduced risk of ventricular arrhythmias in percutaneous coronary intervention patients (n ¼ 1177) with acute myocardial infarction (MI). 1 Moreover, all-cause death at follow-up (12 months) was lower (hazard ratio: 0.191, 95% confidence interval: 0.059-0.618, P ¼ .006) in patients on previous statin treatment. However, there were no significant differences in cardiac death, repeat revascularization, or recurrent MI during follow-up. Prior studies have shown an antiarrhythmic benefit of statin use in various settings. Statins, in addition to low-density lipoprotein cholesterol lowering, exhibited properties of improved endothelial homeostasis, anti-inflammatory, and antioxidant effects and normalization of sympathetic outflow. 2, 3 Experimental studies determined that statin use shortened the duration of the action potential and suppressed trigger activity, thereby reducing the incidence of ventricular arrhythmias. [4] [5] [6] These effects may be dose dependent. 7 Park et al 1 determined similar results. However, we have some concerns about the study. First, there are no data about previous antiarrhythmic and/or b-blocker treatment of patients. Second, the duration and doses of statin treatment are not clear. Finally, there are no data about serum electrolyte levels.
